Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

• Nicolas Martinez-Calle,
• Paula Rodriguez-Otero,
• Sara Villar,
• Luis Mejías,
• Ignacio Melero,
• Felipe Prosper,
• Patricia Marinello,
• Bruno Paiva,
• Miguel Idoate,
• Jesus San-Miguel

Affiliations

Nicolas Martinez-Calle

Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain

Paula Rodriguez-Otero

Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain

Sara Villar

Hematology Department. Clínica Universidad de Navarra, Spain

Luis Mejías

Clinical Department of Pathology, Clínica Universidad de Navarra, Spain

Ignacio Melero

Center for Applied Medical Research (CIMA), University of Navarra, Spain;Clinical Immunology Department, Clínica Universidad de Navarra, Spain

Felipe Prosper

Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain;Centro de Investigación Biomédica en Red, Cancer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

Patricia Marinello

Merck Sharp and Dohme Laboratories, New York City, NY, USA

Bruno Paiva

Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain;CIMALab Diagnostics, University of Navarra, Spain

Miguel Idoate

Clinical Department of Pathology, Clínica Universidad de Navarra, Spain

Jesus San-Miguel

Hematology Department. Clínica Universidad de Navarra, Spain;Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain;Center for Applied Medical Research (CIMA), University of Navarra, Spain;Centro de Investigación Biomédica en Red, Cancer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain